Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
Status:
Recruiting
Trial end date:
2023-03-07
Target enrollment:
Participant gender:
Summary
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic
liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and
fibrosis stage, but will not receive study intervention. In Part B, participants with
histologically confirmed NAFLD or non-alcoholic steatohepatitis (NASH) will receive study
intervention.